Articles by Louis Garguilo

51. A Cost Measurement Pharma Can Live With (CROs/CMOs, Too) 6/2/2015

    Sometimes one finds help in unusual places. This might be one of those times for Pharma, and the place could be AdverseEvents. And Pharma can turn to a more usual partner — CROs/CMOs — to positively influence what AdverseEvents measures.

52. CROs In A Business Exchange With Silicon Valley? 5/29/2015

    As an applied economic theoretic, by driving out inefficiencies from the current model used by researchers to find and contract with CROs, the Science Exchange should improve the business model for drug discovery. But will all parties — Pharma/Bio, CROs and individual researchers — benefit equally? 

53. Not a Sterile Debate On Aseptic Services Crunch 5/4/2015

    Driving the aseptic services sector is positive news, but with a side effect: the breakthroughs in biologics and other increasingly complex products are enabling the creation of exciting new drugs and therapies … but all requiring the “right” capacity and “perfect" compliance at aseptic facilities.

54. Gilead Saves Lives And Healthcare Dollars By Taking Profits 4/6/2015

    It’s affordable worldwide, saves lives and healthcare dollars, allows a company to create more innovative drugs, and validates the biotech business model. Why a negative bias?

55. Measure Lives Gilead Returns, And The Returns It Provides 3/24/2015

    Reporting on the cost of Sovaldi (Sofosbuvir) has confused price and value. Gilead isn't bankrupting healthcare; it's bankrolling the system. When we turn negative on a company like Gilead, we turn on our own well-being. 

56. Profit For Good At Rottendorf Pharmaceuticals 2/10/2015

    The desire to work for a larger cause, to somehow apply whatever we do for a living to benefit society, continues to rise. And that desire can also elevate company revenues. 

57. Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance 2/5/2015

    Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.

58. Biosimilars Part 2: It's All About Dollars Now 2/2/2015

    Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.

59. Biosimilars: A Brief Manifesto of Morality And Markets 1/26/2015

    As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.

60. A Global Forum For Outsourcing (With Simple Objectives) 9/24/2014

    Perhaps the best advice I’ve heard regarding industry conferences is twofold: first, make sure you attend, and second, keep your objectives for attending simple.